Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
9.2.2021 16:00:00 EET | Business Wire | Press release
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005141/en/
The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics®. By cutting through silos and integrating a range of capabilities, outsourced development programs can be further simplified and accelerated, consistent with Quotient’s belief that molecules need to become cures, fast.
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018. Mark Bryant, BGF, said, “It has been a privilege to support the expansion of Arcinova’s world-leading CDMO facility at such a critical part of its growth journey. We wish the team all the best as it moves to the next stage with Quotient Sciences.”
RBC Capital Markets acted as exclusive financial advisor to Quotient Sciences. PwC provided financial and tax due diligence services and Latham & Watkins provided legal counsel. BGF received legal counsel from Weightmans. KPMG served as corporate finance adviser for Arcinova, and Womble Bond Dickinson provided legal counsel.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
About Arcinova
Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. The company, with decades of experience, combines agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products. Arcinova’s ambition is to save our clients valuable time, enabling them to rapidly bring life-changing medicines to market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005141/en/
Contact information
Jane Byram
SCORR Marketing
+1-512-626-2758
jane@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Horse Powertrain Reveals Lightweight Hybrid V6 System at Beijing Auto Show 202622.4.2026 02:01:00 EEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, has revealed the HORSE W30 – the company’s first production-ready V6 engine – ahead of the Beijing Auto Show 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421176701/en/ The front view of the HORSE W30 engine. The HORSE W30 marks a first for Horse Powertrain, in transferring its expertise in developing optimized three- and four-cylinder engines into the V6 category. By deploying its expertise in this way, Horse Powertrain has developed the lightest V6 on the market and created a hybrid-first V6 with outstanding fuel economy and efficiency. The HORSE W30 is a 3-liter engine that can be fitted in a transverse or longitudinal configuration, allowing it to be packaged in a wide variety of vehicles. The two rows of cylinders are offset at an angle of 90° to lower the engine’s center of gravity, improving ease of installation and optimizi
Horse Powertrain Reveals Lightweight Hybrid V6 System at Beijing Auto Show 202622.4.2026 02:01:00 EEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, has revealed the HORSE W30 – the company’s first production-ready V6 engine – ahead of the Beijing Auto Show 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421176701/en/ The front view of the HORSE W30 engine. The HORSE W30 marks a first for Horse Powertrain, in transferring its expertise in developing optimized three- and four-cylinder engines into the V6 category. By deploying its expertise in this way, Horse Powertrain has developed the lightest V6 on the market and created a hybrid-first V6 with outstanding fuel economy and efficiency. The HORSE W30 is a 3-liter engine that can be fitted in a transverse or longitudinal configuration, allowing it to be packaged in a wide variety of vehicles. The two rows of cylinders are offset at an angle of 90° to lower the engine’s center of gravity, improving ease of installation and optimizi
Montrose Environmental Group Is Now Onterris21.4.2026 23:05:00 EEST | Press release
Montrose Environmental Group (NYSE: MEG, changing to ONT May 4, 2026) will mark Earth Day by rebranding to Onterris. The new, unified brand reflects a purpose and broader role in tackling complex environmental challenges with scientific rigor, operational quality and precise execution. It also aligns expertise and market awareness to position the Company for its next phase of growth. Founded 14 years ago and operating across the U.S., Canada and Australia, the Company is a leading pure-play environmental solutions provider. While the name is new, the mission remains unchanged: advancing our way of life without compromising the integrity of our environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420842892/en/ At the heart of the new brand is a guiding principle: For Planet & Progress. “Onterris is more than a new name. This brand reflects our company’s evolution and role in solving some of the defining environmenta
Montrose Environmental Group Is Now Onterris21.4.2026 23:05:00 EEST | Press release
Montrose Environmental Group (NYSE: MEG, changing to ONT May 4, 2026) will mark Earth Day by rebranding to Onterris. The new, unified brand reflects a purpose and broader role in tackling complex environmental challenges with scientific rigor, operational quality and precise execution. It also aligns expertise and market awareness to position the Company for its next phase of growth. Founded 14 years ago and operating across the U.S., Canada and Australia, the Company is a leading pure-play environmental solutions provider. While the name is new, the mission remains unchanged: advancing our way of life without compromising the integrity of our environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420842892/en/ At the heart of the new brand is a guiding principle: For Planet & Progress. “Onterris is more than a new name. This brand reflects our company’s evolution and role in solving some of the defining environmenta
SBC Medical Announces Closing of Previously Announced Secondary Public Offering of 3.1 million shares of Common Stock21.4.2026 23:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the closing of its previously announced underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. The proceeds from the offering to the Selling Stockholder were approximately $10.1 million, before deducting underwriting discounts and commissions. The Company did not sell any shares of its common stock in the offering. The Selling Stockholder received all of the proceeds from the offering. Maxim Group LLC acted as the sole book-running manager and Roth Capital Partners acted as the co-manager for the offering. The offering was made pursuant to the Company’s effective shelf registration statement on Form S-3, including a base prospectus, filed with the U.S. Secur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom